title: Once-a-month treatment with a combination of mifepristone and the prostaglandin analogue misoprostol.
abstract: In this two centre study, the efficacy of 200 mg mifepristone orally followed 48 h later by 0.4 mg misoprostol orally for menstrual regulation was investigated. The dose of mifepristone was taken the day before the expected day of menstruation. Each volunteer was planned to participate for up to 6 months. A plasma beta human chorionic gonadotrophin (HCG) was measured on the day of mifepristone intake. The study was disrupted prematurely due to low efficacy. In 125 treatment cycles the overall pregnancy rate was 17.6% (22 pregnancies) and the rate of continuing pregnancies (failure) was 4.0%. Eight women discontinued the study due to bleeding irregularities which were seen in 15 cycles (12%). These effects on bleeding pattern made the timing of treatment day difficult. Late luteal phase treatment with a combination of mifepristone and misoprostol is not adequately effective for menstrual regulation.
authors: Department of Obstetrics and Gynecology, Huddinge University Hospital, Sweden.
authors: M L
authors: ML
authors: Swahn
authors: M
authors: M
authors: Bygdeman
authors: J K
authors: JK
authors: Chen
authors: K
authors: K
authors: Gemzell-Danielsson
authors: S
authors: S
authors: Song
authors: Q Y
authors: QY
authors: Yang
authors: P J
authors: PJ
authors: Yang
authors: M L
authors: ML
authors: Qian
authors: W F
authors: WF
authors: Chang
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage* / Q000627:therapeutic use; D000028:Abortion, Induced; D000328:Adult; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007986:Luteinizing Hormone / Q000652:urine; D008597:Menstrual Cycle / Q000187:drug effects; D008600:Menstruation-Inducing Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D015735:Mifepristone / Q000008:administration & dosage* / Q000627:therapeutic use; D016595:Misoprostol / Q000008:administration & dosage* / Q000627:therapeutic use; D011247:Pregnancy; D011453:Prostaglandins / Q000008:administration & dosage* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D004338:Drug Combinations; D008600:Menstruation-Inducing Agents; D011453:Prostaglandins; D016595:Misoprostol; D015735:Mifepristone; D007986:Luteinizing Hormone